With one rival down, Novartis-partnered biotech scores $100M round to fund mid-stage trials of fibrosis drug

With one rival down, Novartis-partnered biotech scores $100M round to fund mid-stage trials of fibrosis drug

Submitted by admin on March 3, 2020 - 11:02am
Source: 
Endpoints
News Tags: 
Pliant Therapeutics
IPF
Biogen
Novartis
Headline: 
With one rival down, Novartis-partnered biotech scores $100M round to fund mid-stage trials of fibrosis drug
snippet: 

When Pliant Therapeutics bagged its $62 million B round almost two years ago, CEO Bernard Coulie positioned its lead program in idiopathic pulmonary fibrosis right behind Biogen, which he sees as a frontrunner 18 months ahead.

Do Not Allow Advertisers to Use My Personal information